It’s not but it is also a) a selected example of many to illustrate a point with clarity, b) a widely emulated model, c) essentially what the company who pivoted pivoted towards. Rather than a one time solution, a reoccurring subscription model, so is salient and likely it or a similar model was considered in that switch.
I agree. Sadly most investors risking capital don’t. That’s why I love these guys and hope they get their funding. I imagine they fall outside some kickstarted T&C prohibiting bioengineering for use in humans, and likely Patreon too, but I would definitely kick over some bucks to help them if there were a channel.
